Ocular Surface Microbiota-Derived Lipoteichoic Acid Promotes Dry Eye Disease by Inducing Corneal Inflammation
Investigative Ophthalmology & Visual Science · 24.03.2026 · 67 (3) · 50
DOI: 10.1167/iovs.67.3.50 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 24.03.2026. Verfasst von Qingyu An und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Teichoic Acids, Dry Eye Syndromes, Lipopolysaccharides, Keratitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Ocular surface microbiota (OSM) dysbiosis is associated with dry eye disease (DED), but the underlying mechanisms remain poorly understood. This study investigated the role of lipoteichoic acid (LTA), a Gram-positive bacterial product, in DED pathogenesis.
Methods
A cross-sectional study was conducted involving 277 participants to analyze OSM composition via 16S rRNA sequencing and quantify tear LTA levels. In vitro experiments using human corneal epithelial cells (HCE-T) and in vivo mouse models were used to explore LTA-induced inflammation. The involvement of Toll-like receptor 2 (TLR2) and platelet-activating factor receptor (PAFR) was assessed using siRNAs and the PAFR antagonist Apafant.
Results
Patients with DED showed functional enrichment in LTA synthesis-related pathways in their OSM. Tear LTA levels were significantly elevated in patients with DED and correlated positively with disease risk and clinical severity. Mechanistically, LTA activated p38 MAPK and NF-κB signaling pathways via TLR2 and PAFR, upregulating pro-inflammatory cytokine expression. In mice, topical LTA administration induced corneal epithelial damage, reduced tear secretion, and caused histopathological changes. Treatment with Apafant significantly alleviated LTA-induced corneal inflammation, improved tear secretion, and preserved epithelial integrity.
Conclusions
Our findings establish a mechanistic link between OSM-derived LTA and DED. LTA promotes ocular surface inflammation and dysfunction through TLR2 and PAFR signaling, suggesting that targeting microbial products or their receptors, such as PAFR, may offer a novel therapeutic strategy for DED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
- Shanghai Key Laboratory of Fundus Diseases, Shanghai, People's Republic of China.
- Shanghai Eye Diseases Prevention and Treatment Center/ Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
- National Clinical Research Center for Eye Diseases, Shanghai, People's Republic of China.
- Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, People's Republic of China.
Zitieren
APA
An, Q., Qin, X., Zhong, L., Cui, L., Lu, L., Xu, Y., Lin, S., & Zou, H. (2026). Ocular Surface Microbiota-Derived Lipoteichoic Acid Promotes Dry Eye Disease by Inducing Corneal Inflammation. Investigative Ophthalmology & Visual Science, 67(3), 50. https://doi.org/10.1167/iovs.67.3.50
Vancouver
An Q, Qin X, Zhong L, Cui L, Lu L, Xu Y, et al. Ocular Surface Microbiota-Derived Lipoteichoic Acid Promotes Dry Eye Disease by Inducing Corneal Inflammation. Investigative Ophthalmology & Visual Science. 2026;67(3):50. doi:10.1167/iovs.67.3.50
BibTeX
@article{An2026,
author = {An, Qingyu and Qin, Xinran and Zhong, Lei and Cui, Lipu and Lu, Lina and Xu, Yi and Lin, Senlin and Zou, Haidong},
title = {Ocular Surface Microbiota-Derived Lipoteichoic Acid Promotes Dry Eye Disease by Inducing Corneal Inflammation},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {3},
pages = {50},
doi = {10.1167/iovs.67.3.50}
}
EUVIMED